[HTML][HTML] A guide to immunotherapy for COVID-19
FL van de Veerdonk, E Giamarellos-Bourboulis… - Nature medicine, 2022 - nature.com
Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …
large body of literature has reported the effect of immune-based therapies in patients with …
Risk factors for severe and critically ill COVID‐19 patients: a review
Y Gao, M Ding, X Dong, J Zhang, A Kursat Azkur… - Allergy, 2021 - Wiley Online Library
The pandemic of coronavirus disease 2019 (COVID‐19), caused by the severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused an unprecedented global …
respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused an unprecedented global …
[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis
K Kaushal, H Kaur, P Sarma, A Bhattacharyya… - Journal of critical …, 2022 - Elsevier
Ferritin is a known inflammatory biomarker in COVID-19. However, many factors and co-
morbidities can confound the level of serum ferritin. This current metaanalysis evaluates …
morbidities can confound the level of serum ferritin. This current metaanalysis evaluates …
[HTML][HTML] Calming the cytokine storm in COVID-19
RQ Cron, R Caricchio, WW Chatham - Nature medicine, 2021 - nature.com
Calming the cytokine storm in COVID-19 | Nature Medicine Skip to main content Thank you for
visiting nature.com. You are using a browser version with limited support for CSS. To obtain the …
visiting nature.com. You are using a browser version with limited support for CSS. To obtain the …
[HTML][HTML] Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation
LJH Rasmussen, JEV Petersen… - Frontiers in …, 2021 - frontiersin.org
Systemic chronic inflammation (SCI) is persistent, health-damaging, low-grade inflammation
that plays a major role in immunosenescence and in development and progression of many …
that plays a major role in immunosenescence and in development and progression of many …
An open label trial of anakinra to prevent respiratory failure in COVID-19
E Kyriazopoulou, P Panagopoulos, S Metallidis… - Elife, 2021 - elifesciences.org
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR≥ 6 ng/ml …
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR≥ 6 ng/ml …
Inflammation, hyperglycemia, and adverse outcomes in individuals with diabetes mellitus hospitalized for COVID-19
A Vasbinder, E Anderson, H Shadid, H Berlin… - Diabetes …, 2022 - Am Diabetes Assoc
OBJECTIVE Diabetes mellitus (DM) is a major risk factor for severe coronavirus disease
2019 (COVID-19) for reasons that are unclear. RESEARCH DESIGN AND METHODS We …
2019 (COVID-19) for reasons that are unclear. RESEARCH DESIGN AND METHODS We …
Current evidence on the use of anakinra in COVID-19
Despite the progressing knowledge in COVID-19 management, remdesivir is the only agent
that got approval to inhibit viral replication. However, there are limited data about effective …
that got approval to inhibit viral replication. However, there are limited data about effective …
COVID-19 and acute kidney injury
In December 2019, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was discovered in Wuhan, China, the rapid spread of which culminated in a global …
was discovered in Wuhan, China, the rapid spread of which culminated in a global …